

CD3EAP Blocking Peptide (N-term)

Synthetic peptide

Catalog # BP19997a

Specification

CD3EAP Blocking Peptide (N-term) - Product Information

Primary Accession

[O15446](#)

Other Accession

[NP_036231.1](#)**CD3EAP Blocking Peptide (N-term) - Additional Information****Gene ID** 10849**Other Names**

DNA-directed RNA polymerase I subunit RPA34, A345, Antisense to ERCC-1 protein, ASE-1, CD3-epsilon-associated protein, CAST, CD3E-associated protein, RNA polymerase I-associated factor PAF49, CD3EAP, ASE1, CAST, PAF49

Target/Specificity

The synthetic peptide sequence is selected from aa 69-81 of HUMAN CD3EAP

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CD3EAP Blocking Peptide (N-term) - Protein Information**Name** POLR1G ([HGNC:24219](#))**Function**

Component of RNA polymerase I (Pol I), a DNA-dependent RNA polymerase which synthesizes ribosomal RNA precursors using the four ribonucleoside triphosphates as substrates. Involved in UBTF-activated transcription, presumably at a step following PIC formation.

Cellular Location

Nucleus, nucleolus. Chromosome. Note=Found at the fibrillar centers of the nucleolus in interphase and during cell division it is localized to the nucleolus organizer regions of the chromosomes

CD3EAP Blocking Peptide (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CD3EAP Blocking Peptide (N-term) - Images

CD3EAP Blocking Peptide (N-term) - Background

DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Component of RNA polymerase I which synthesizes ribosomal RNA precursors. Isoform 1 is involved in UBTF-activated transcription, presumably at a step following PIC formation.

Isoform 2 has been described as a component of preformed T-cell receptor (TCR) complex.

CD3EAP Blocking Peptide (N-term) - References

Guey, L.T., et al. Eur. Urol. 57(2):283-292(2010)
Hosgood, H.D. III, et al. Occup Environ Med 66(12):848-853(2009)
Vangsted, A.J., et al. Haematologica 94(9):1274-1281(2009)
Nissen, K.K., et al. Anticancer Drugs 20(3):174-178(2009)
Schierup, M.H., et al. BMC Med. Genet. 10, 20 (2009) :